Skip to content

A Study of Orally Administered MOMA-313 in Participants with Advanced or Metastatic Solid Tumours

Status
Recruiting
Phases
Phase 1
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2024-513502-62-00
Acronym
MOMA-313-001
Enrollment
48
Registered
2025-02-18
Start date
2025-03-07
Completion date
Unknown
Last updated
2026-01-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced or Metastatic Solid Tumors

Interventions

None listed

Sponsors

Moma Therapeutics Inc.
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Countries

Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026